Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke

被引:118
|
作者
Ernst, R
Pancioli, A
Tomsick, T
Kissela, B
Woo, D
Kanter, D
Jauch, E
Carrozzella, J
Spilker, J
Broderick, J
机构
[1] Univ Cincinnati, Med Ctr, Dept Radiol, Neuroradiol Sect, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Med Ctr, Dept Emergency Med, Cincinnati, OH 45267 USA
[3] Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45267 USA
关键词
fibrinolysis; stroke; acute; ischemic; thrombolysis; tissue plasminogen activator;
D O I
10.1161/01.STR.31.11.2552
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-A retrospective analysis was performed on 20 consecutive patients who presented with severe acute ischemic stroke and were evaluated for a combined intravenous (IV) and local intra-arterial (IA) recombinant tissue plasminogen activator (rtPA) thrombolytic approach within 3 hours of onset. Methods-Twenty consecutive patients with carotid artery distribution strokes were evaluated and treated using a combined IV and IA rtPA approach over a 14-month period (September 1998 to October 1999). rtPA (0.6 mg/kg) was given intravenously (maximum dose 60 mg); 15% of the IV dose was given as bolus, followed by a continuous infusion over 30 minutes. A maximal IA dose, up to 0.3 mg/kg or 24 mg, whichever was less, was given over a maximum of 2 hours. IV treatment was initiated within 3 hours in 19 of 20 patients. All 20 patients underwent angiography, and 16 of 20 patients received local IA rtPA. Results-The median baseline National Institutes of Health Stroke Scale (NIHSS) score for the 20 patients was 21 (range 11 to 31). The median time from stroke onset to IV treatment was 2 hours and 2 minutes, and median time to initiation of IA treatment was 3 hours and 30 minutes. Ten patients (50%) recovered to a modified Rankin Scale (mRS) of 0 or 1; 3 patients (15%), to an mRS of 2; and 5 patients (25%), to an mRS of 4 or 5. One patient (5%) developed a symptomatic intracerebral hemorrhage and eventually died. One other patient (5%) expired because of complications from the stroke. Conclusions-We believe that the greater-than-expected proportion of favorable outcomes in these patients with severe ischemic stroke reflects the shea time to initiation of both IV and IA thrombolysis.
引用
收藏
页码:2552 / 2557
页数:6
相关论文
共 50 条
  • [41] Acute ischemic stroke: improving access to intravenous tissue plasminogen activator
    Turner, Ashby C.
    Schwamm, Lee H.
    Etherton, Mark R.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (05) : 277 - 287
  • [42] Safety and efficacy of intravenous tissue plasminogen activator in acute ischemic stroke
    Rajapa, S.
    Sivakumar, S.
    Arjundas, D.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 133 - 133
  • [43] Results of combined intravenous and intra-arterial thrombolysis based on MR angiography during intravenous recombinant tissue plasminogen activator infusion - single-centre experiences from acute ischaemic stroke thrombolysis registry
    Suh, C. K.
    Kim, Y. W.
    Hwang, Y. H.
    Park, S. P.
    Kang, D. H.
    Kim, Y. S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S196 - S196
  • [44] Safety and Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients on Aspirin and Clopidogrel
    Qureshi, Mushtaq H.
    Khan, Shayaan M.
    Jahangir, Nauman
    Malik, Ahmed A.
    Freese, Melissa
    Thompson, Michelle
    Khan, Asif A.
    Suri, M. Fareed K.
    Qureshi, Adnan I.
    STROKE, 2015, 46
  • [45] Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients With Recent Myocardial Infarction.
    Inohara, Taku
    Liang, Li
    Kosinski, Andrzej
    Smith, Eric E.
    Schwamm, Lee H.
    Hernandez, Adrian F.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Peterson, Eric D.
    Xian, Ying
    STROKE, 2019, 50
  • [46] Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke
    Laible, Mona
    Jenetzky, Ekkehardt
    Moehlenbruch, Markus
    Ringleb, Peter Arthur
    Rizos, Timolaos
    EUROPEAN NEUROLOGY, 2015, 74 (3-4) : 127 - 134
  • [47] Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
    Chapman, Sherita N.
    Mehndiratta, Prachi
    Johansen, Michelle C.
    McMurry, Timothy L.
    Johnston, Karen C.
    Southerland, Andrew M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 75 - 87
  • [48] Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
    Hong, Keun-Sik
    Park, So-Young
    Whang, Seon-Il
    Seo, So-Young
    Lee, Dong-Ha
    Kim, Han-Joon
    Cho, Joong-Yang
    Cho, Yong-Jin
    Jang, Woo-Ik
    Kim, Chang Young
    JOURNAL OF CLINICAL NEUROLOGY, 2009, 5 (01): : 49 - 52
  • [49] Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients With Gastrointestinal Malignancy or Recent Bleeding
    Inohara, Taku
    Liang Li
    Kosinski, Andrzej
    Smith, Eric E.
    Schwamm, Lee H.
    Hernandez, Adrian F.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Peterson, Eric D.
    Xian Ying
    CIRCULATION, 2018, 138
  • [50] Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator
    Betts, Keith A.
    Hurley, Dana
    Song, Jinlin
    Sajeev, Gautam
    Guo, Jenny
    Du, Ella Xiaoyan
    Paschoalin, Marco
    Wu, Eric Q.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (09): : 1996 - 2003